SG Americas Securities LLC Makes New $131,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

SG Americas Securities LLC bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,707 shares of the company’s stock, valued at approximately $131,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in UroGen Pharma during the third quarter valued at approximately $20,787,000. Stonepine Capital Management LLC raised its holdings in shares of UroGen Pharma by 16.1% in the fourth quarter. Stonepine Capital Management LLC now owns 1,304,947 shares of the company’s stock worth $11,575,000 after buying an additional 180,727 shares during the last quarter. BlackRock Inc. raised its holdings in shares of UroGen Pharma by 285.9% in the second quarter. BlackRock Inc. now owns 1,097,916 shares of the company’s stock worth $11,363,000 after buying an additional 813,377 shares during the last quarter. Millennium Management LLC raised its holdings in shares of UroGen Pharma by 292.8% in the second quarter. Millennium Management LLC now owns 616,245 shares of the company’s stock worth $5,047,000 after buying an additional 459,341 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of UroGen Pharma by 8.3% in the first quarter. State Street Corp now owns 548,241 shares of the company’s stock worth $4,775,000 after buying an additional 41,886 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on URGN shares. HC Wainwright reaffirmed a “buy” rating and issued a $54.00 price target on shares of UroGen Pharma in a report on Thursday, April 4th. Oppenheimer decreased their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a report on Friday, March 15th.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $14.24 on Thursday. The firm has a market capitalization of $333.93 million, a P/E ratio of -3.82 and a beta of 1.07. UroGen Pharma Ltd. has a 1-year low of $8.69 and a 1-year high of $24.13. The company’s fifty day moving average price is $16.38 and its 200-day moving average price is $14.59.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analysts’ expectations of $22.30 million. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.59 EPS for the current fiscal year.

Insider Transactions at UroGen Pharma

In other news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total value of $168,600.00. Following the sale, the insider now owns 139,437 shares in the company, valued at $1,959,089.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, General Counsel Jason Drew Smith sold 4,993 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $78,589.82. Following the sale, the general counsel now owns 18,824 shares in the company, valued at $296,289.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark Schoenberg sold 12,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total transaction of $168,600.00. Following the sale, the insider now owns 139,437 shares in the company, valued at approximately $1,959,089.85. The disclosure for this sale can be found here. Insiders have sold 20,782 shares of company stock worth $306,829 over the last 90 days. 11.13% of the stock is currently owned by company insiders.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.